Baidu
map

2013-2014年期刊变更情况一览

2015-06-19 MedSci MedSci原创

无标题文档 <!-- .STYLE1 {font-family: Arial, Helvetica, sans-serif} .STYLE3 { font-family: Arial, Helvetica, sans-serif; font-size: 18px; color: #FFFFFF; } .STYLE4 {color: #FFFFFF} -->

每年影响因子公布时,都是几家欢喜几家愁!
我的目标杂志影响因子升了,但是他刚投的期刊竟然从SCI中被剔除了!
啊,还有被镇压杂志,这个你知道是什么意思吗?还有翻身的机会吗?

投稿不难,把握最新消息最重要。官方或小道,我们都喜欢:MedSci 2015年期刊智能查询系统(2014年度) 给你最新的杂志投稿信息

网页查询不方便?简单,我们已经将所有的信息搬到手机上了,下载:SCI期刊助手,享受最简介智能的查询工具吧,这也许是国内最强大的期刊助手!


无标题文档
2013-2014年期刊变更情况一览
期刊名
变化状态
期刊名
变更时间
ACTA METEOROL SIN changed to J METEOROL RES-PRC
2014
ADV VIB ENG changed to J VIB ENG TECHNOL
2014
ANDROLOGY-US merged from INT J ANDROL
2013
ANDROLOGY-US merged from J ANDROL
2013
ANN GLOB HEALTH changed from MT SINAI J MED
2014
ANN SURG TREAT RES changed from J KOREAN SURG SOC
2014
ARCH DERMATOL changed to JAMA DERMATOL
2013
ARCH FACIAL PLAST S changed to JAMA FACIAL PLAST SU
2013
ARCH GEFLUGELKD changed to EUR POULTRY SCI
2014
ARCH GEN PSYCHIAT changed to JAMA PSYCHIAT
2013
ARCH INTERN MED changed to JAMA INTERN MED
2013
ARCH NEUROL-CHICAGO changed to JAMA NEUROL
2013
ARCH OPHTHALMOL-CHIC changed to JAMA OPHTHALMOL
2013
ARCH OTOLARYNGOL changed to JAMA OTOLARYNGOL
2013
ARCH PEDIAT ADOL MED changed to JAMA PEDIATR
2013
ARCH RHEUMATOL changed from TURK J RHEUMATOL
2014
ARCH SURG-CHICAGO changed to JAMA SURG
2013
ARTHRITIS RHEUM-US changed to ARTHRITIS RHEUMATOL
2014
ARTHRITIS RHEUMATOL changed from ARTHRITIS RHEUM-US
2014
ARTIF CELL BLOOD SUB changed to ARTIF CELL NANOMED B
2013
ARTIF CELL NANOMED B changed from ARTIF CELL BLOOD SUB
2013
ASLIB J INFORM MANAG changed from ASLIB PROC
2014
ASLIB PROC changed to ASLIB J INFORM MANAG
2014
AUST J ENTOMOL changed to AUSTRAL ENTOMOL
2014
AUSTRAL ENTOMOL changed from AUST J ENTOMOL
2014
BIOMED RES INT changed from J BIOMED BIOTECHNOL
2013
BONE JOINT J changed from J BONE JOINT SURG BR
2013
CAN J PLAST SURG changed to PLAST SURG-CHIR PLAS
2014
CIENCIA TECNOL ALIME changed to FOOD SCI TECH-BRAZIL
2013
CLIN DEV IMMUNOL changed to J IMMUNOL RES
2014
COMP FUNCT GENOM changed to INT J GENOMICS
2013
DRUG INF J changed to THER INNOV REGUL SCI
2013
ECS SOLID STATE LETT split from ELECTROCHEM SOLID ST
2013
ELECTROCHEM SOLID ST split into ECS SOLID STATE LETT
2013
ENVIRON SCI-PROC IMP changed from J ENVIRON MONITOR
2013
EUR POULTRY SCI changed from ARCH GEFLUGELKD
2014
EUR T ELECTR POWER changed to INT T ELECTR ENERGY
2013
EXP DIABETES RES changed to J DIABETES RES
2013
FEMS IMMUNOL MED MIC changed to PATHOG DIS
2013
FOOD SCI TECH-BRAZIL changed from CIENCIA TECNOL ALIME
2013
IEEE J BIOMED HEALTH changed from IEEE T INF TECHNOL B
2013
IEEE T AUDIO SPEECH changed to IEEE-ACM T AUDIO SPE
2014
IEEE T CYBERNETICS changed from IEEE T SYST MAN CY B
2013
IEEE T HUM-MACH SYST changed from IEEE T SYST MAN CY C
2013
IEEE T INF TECHNOL B changed to IEEE J BIOMED HEALTH
2013
IEEE T SYST MAN CY B changed to IEEE T CYBERNETICS
2013
IEEE T SYST MAN CY C changed to IEEE T HUM-MACH SYST
2013
IEEE-ACM T AUDIO SPE changed from IEEE T AUDIO SPEECH
2014
INT J ANDROL merged into ANDROLOGY-US
2013
INT J GENOMICS changed from COMP FUNCT GENOM
2013
INT J RADIAT RES changed from IRAN J RADIAT RES
2013
INT T ELECTR ENERGY changed from EUR T ELECTR POWER
2013
IRAN J ENVIRON HEALT changed to J ENVIRON HEALTH SCI
2013
IRAN J RADIAT RES changed to INT J RADIAT RES
2013
J AEROS COMP INF COM changed to J AEROSP INFORM SYST
2013
J AEROSP INFORM SYST changed from J AEROS COMP INF COM
2013
J AM ACAD NURSE PRAC changed to J AM ASSOC NURSE PRA
2014
J AM ASSOC NURSE PRA changed from J AM ACAD NURSE PRAC
2014
J AM SOC INF SCI TEC changed to J ASSOC INF SCI TECH
2014
J ANDROL merged into ANDROLOGY-US
2013
J ASSOC INF SCI TECH changed from J AM SOC INF SCI TEC
2014
J BIOMED BIOTECHNOL changed to BIOMED RES INT
2013
J BONE JOINT SURG BR changed to BONE JOINT J
2013
J DIABETES RES changed from EXP DIABETES RES
2013
J ELECTRON MICROSC changed to MICROSCOPY-JPN
2013
J ENERGY CHEM changed from J NAT GAS CHEM
2013
J ENG RES-KUWAIT split from KUWAIT J SCI ENG
2014
J ENVIRON HEALTH SCI changed from IRAN J ENVIRON HEALT
2013
J ENVIRON MONITOR changed to ENVIRON SCI-PROC IMP
2013
J IMMUNOL RES changed from CLIN DEV IMMUNOL
2014
J KOREAN SURG SOC changed to ANN SURG TREAT RES
2014
J METEOROL RES-PRC changed from ACTA METEOROL SIN
2014
J NAT GAS CHEM changed to J ENERGY CHEM
2013
J ORAL FACIAL PAIN H changed from J OROFAC PAIN
2014
J OROFAC PAIN changed to J ORAL FACIAL PAIN H
2014
J VIB ENG TECHNOL changed from ADV VIB ENG
2014
JAMA DERMATOL changed from ARCH DERMATOL
2013
JAMA FACIAL PLAST SU changed from ARCH FACIAL PLAST S
2013
JAMA INTERN MED changed from ARCH INTERN MED
2013
JAMA NEUROL changed from ARCH NEUROL-CHICAGO
2013
JAMA OPHTHALMOL changed from ARCH OPHTHALMOL-CHIC
2013
JAMA OTOLARYNGOL changed from ARCH OTOLARYNGOL
2013
JAMA PEDIATR changed from ARCH PEDIAT ADOL MED
2013
JAMA PSYCHIAT changed from ARCH GEN PSYCHIAT
2013
JAMA SURG changed from ARCH SURG-CHICAGO
2013
JOHNSON MATTHEY TECH changed from PLATIN MET REV
2014
KUWAIT J SCI ENG split into J ENG RES-KUWAIT
2014
METALL RES TECHNOL changed from REV METALL-PARIS
2014
MICROSCOPY-JPN changed from J ELECTRON MICROSC
2013
MT SINAI J MED changed to ANN GLOB HEALTH
2014
MULTISENS RES changed from SEEING PERCEIVING
2013
NPJ PRIM CARE RESP M changed from PRIM CARE RESP J
2014
PATHOG DIS changed from FEMS IMMUNOL MED MIC
2013
PLANT REPROD changed from SEX PLANT REPROD
2013
PLAST SURG-CHIR PLAS changed from CAN J PLAST SURG
2014
PLATIN MET REV changed to JOHNSON MATTHEY TECH
2014
PRIM CARE RESP J changed to NPJ PRIM CARE RESP M
2014
REV FISH SCI changed to REV FISH SCI AQUAC
2014
REV FISH SCI AQUAC changed from REV FISH SCI
2014
REV METALL-PARIS changed to METALL RES TECHNOL
2014
SCAND J UROL changed from SCAND J UROL NEPHROL
2013
SCAND J UROL NEPHROL changed to SCAND J UROL
2013
SEEING PERCEIVING changed to MULTISENS RES
2013
SEX PLANT REPROD changed to PLANT REPROD
2013
THER INNOV REGUL SCI changed from DRUG INF J
2013
TRANSPORTMETRICA split into TRANSPORTMETRICA B
2013
TRANSPORTMETRICA B split from TRANSPORTMETRICA
2013
TURK J RHEUMATOL changed to ARCH RHEUMATOL
2014
UROL RES changed to UROLITHIASIS
2013
UROLITHIASIS changed from UROL RES
2013

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    这篇文章很有价值

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    让我们了解了最新的实况

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    非常感谢作者

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 caierhong

    好文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=34870, encodeId=ecdc348e0ee, content=这篇文章很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34871, encodeId=bdaf348e11e, content=让我们了解了最新的实况, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34872, encodeId=bed0348e237, content=非常感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 16:38:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29167, encodeId=3faa2916ed1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28567, encodeId=8a0b2856ebc, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28543, encodeId=09e92854357, content=争取中, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 18:56:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 erhong

    争取中

    0

相关资讯

期刊为何愿意接受会议论文发表?质量如何保证?

一般来说,期刊很乐意接受一些优秀的会议论文,特别是国际稿件。因为会议论文具有新颖性、前沿性;大多涉及热点问题、吸引眼球的内容。这样的论文将能提高期刊引用率。相对地,那些工艺类和技术类论文关注度稍低。会议稿件质量的控制是期刊编辑和会议组织者面临的重要挑战。制约因素有:一、经济与时间的考量;经济因素应该是会议举办者首要考虑的。稿件质量与会议承办者的承诺之间必须有相应的平衡。据稿率高,开会的人少,这不是

如何在国际学术期刊上发表论文?

作为研究生,大家一定有个共同的心愿——发文章!小编就为大家介绍一些发文技巧。1.目的决定一片论文是否可以发表的最重要因素是论文中所阐述思想的好坏。实际中,非实质性的因素,如论文的包装,也会成为论文是否发表的影响因素。1.1.为什么期刊的接受率这么低提交给国际有影响的期刊论文,一般只有1/3的作者能够受到略微积极的反馈;其他则都为否定。如果有两个匿名评审人评审一篇论文,那么一篇平均质量的论文被两

投文章前,先搞清SCI、EI、ISTP、SSCI、CSSCI和CSCD吧!

导语:随着科研国际化的普及,越来越多的高校及研究所要求研究生们在国际期刊上投稿发文。然而对于一些刚入门科研界的研究生们,在投稿前,应该先搞清SCI、EI、ISTP、SSCI、CSSCI和CSCD的涵义与特征。SCI 是美国《科学引文索引》的英文简称,其全称为:Science Citation Index,,创刊于1961年,它是根据现代情报学家加菲尔德(Engene Garfield)

JAMA Oncology创刊--一本新的肿瘤领域期刊

在接下来的20年预计划全球范围内的患者初诊为癌症的人数可达1400万,每年增加22亿美元医疗费用,全球范围每年的癌症死亡人数预计将从820万增长到1300万。但过去十年,肿瘤学也取得突飞猛进的发展,包括癌基因靶向的单克隆抗体,如曲妥珠单抗和西妥昔单抗,针对由crizotinib抑制ALK肺癌,阻断免疫检查点成为肿瘤免疫治疗的新方向,评估癌症基因组为癌症预后和治疗提供全新的计划。癌症治疗已经成为个性

四川大学主办英文学术期刊Bone Research被SCI数据库收录

近日,由口腔疾病研究国家重点实验室、华西口腔医院主办的英文学术期刊Bone Research(BR)被Web of Science接收。自2012年创刊以来发表的所有文章,将进入SCI数据库,这是川大华西口腔医学院主办的第二本英文杂志成功被SCI收录。BR将成为连接世界与中国、口腔医学与医学的重要桥梁,为广大研究者提供高水平的学术交流平台。 经教育部及国家新闻出版总署批准,四川大学主办《

“自然指数”涵盖的68种自然科学期刊名录

在Nature出版集团的推动下,“自然指数”(nature index)现已成为衡量国家与科研单位(大学)科研水平的新的指标,“自然指数”的依据仅是下面这68家期刊.而发表在其他期刊的论文皆不在“自然指数”统计之列。68家期刊,是因为Nature集团基于学界的评价,把它们看成是科学界各学科最好的学术期刊,有人甚至认为,没有在这些期刊经常发表文章,就等于远离前沿,而且对你单位的学术影响力(“自

Baidu
map
Baidu
map
Baidu
map